ArticleBMC cancer2024

Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy.

Amaris Balitsky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.